Physician profile
Snehal Patel
NPI 1477689792
$1,541.01
in general payments reported to CMS, 2019-2025
14 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $52.38 · 2021: $178 · 2022: $121 · 2023: $224 · 2024: $591 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.36 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.40 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.42 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $224.47 | 2021-2025 | |
| Travere Therapeutics, INC. | $170.41 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $166.24 | 2023-2024 | Tarpeyo |
| Baxter Healthcare | $115.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.94 | 2024 | |
| Horizon Therapeutics Plc | $78.27 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $73.25 | 2022-2023 | Veltassa, Korsuva |
| Amgen INC. | $64.54 | 2021-2024 | Krystexxa |
| Fresenius USA Marketing, INC. | $24.84 | 2024 | |
| Glaxosmithkline, LLC. | $12.96 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Snehal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.